Stephen David Prior's most recent trade in AN2 Therapeutics Inc was a trade of 56,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AN2 Therapeutics Inc | Stephen David Prior | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 56,000 | 56,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Stephen David Prior | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 28,000 | 61,313 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Stephen David Prior | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 1.34 per share. | 03 Jan 2025 | 2,029 | 33,313 | - | 1.3 | 2,721 | Common Stock |
| AN2 Therapeutics Inc | Stephen David Prior | Chief Strategy Officer | 04 Nov 2024 | 20,250 | 20,250 | - | - | Stock Option (right to buy) | ||
| AN2 Therapeutics Inc | Stephen David Prior | Chief Strategy Officer | 04 Nov 2024 | 10,125 | 35,342 | - | 0 | Common Stock |